» Articles » PMID: 34408216

A Novel Prognostic Signature of Immune-related LncRNA Pairs in Lung Adenocarcinoma

Overview
Journal Sci Rep
Specialty Science
Date 2021 Aug 19
PMID 34408216
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Lung adenocarcinoma (LUAD) is the most common subtype of lung cancer, but the prognosis of LUAD patients remains unsatisfactory. Here, we retrieved the RNA-seq data of LUAD cohort from The Cancer Genome Atlas (TCGA) database and then identified differentially expressed immune-related lncRNAs (DEirlncRNAs) between LUAD and normal controls. Based on a new method of cyclically single pairing along with a 0-or-1 matrix, we constructed a novel prognostic signature of 8 DEirlncRNA pairs in LUAD with no dependence upon specific expression levels of lncRNAs. This prognostic model exhibited significant power in distinguishing good or poor prognosis of LUAD patients and the values of the area under the curve (AUC) were all over 0.70 in 1, 3, 5 years receiver operating characteristic (ROC) curves. Moreover, the risk score of the model could serve as an independent prognostic factor for patients with LUAD. In addition, the risk model was significantly associated with clinicopathological characteristics, tumor-infiltrating immune cells, immune-related molecules and sensitivity of anti-tumor drugs. This novel signature of DEirlncRNA pairs in LUAD, which did not require specific expression levels of lncRNAs, might be used to guide the administration of patients with LUAD in clinical practice.

Citing Articles

Development of a prognostic model based on different disulfidptosis related genes typing for kidney renal clear cell carcinoma.

Feng Y, Wang W, Jiang S, Liu Y, Wang Y, Zhan X Front Pharmacol. 2024; 15:1343819.

PMID: 38549669 PMC: 10976849. DOI: 10.3389/fphar.2024.1343819.


LINC00958 may be a new prognostic biomarker in various cancers: A meta-analysis and bioinformatics analysis.

Zhang H, Zhang G, Zhang F, Yang X, Li E, Wang B Front Genet. 2022; 13:998442.

PMID: 36437914 PMC: 9691855. DOI: 10.3389/fgene.2022.998442.


Novel Prognosis and Therapeutic Response Model of Immune-Related lncRNA Pairs in Clear Cell Renal Cell Carcinoma.

Wang G, Liu P, Li J, Jin K, Zheng X, Xie L Vaccines (Basel). 2022; 10(7).

PMID: 35891325 PMC: 9325030. DOI: 10.3390/vaccines10071161.


An Immune-Related Long Noncoding RNA Pair as a New Biomarker to Predict the Prognosis of Patients in Breast Cancer.

Jiang H, Sun J, Liu F, Wu X, Wen Z Front Genet. 2022; 13:895200.

PMID: 35812755 PMC: 9257047. DOI: 10.3389/fgene.2022.895200.


Evaluating the tumor immune profile based on a three-gene prognostic risk model in HER2 positive breast cancer.

Lin J, Zhao A, Fu D Sci Rep. 2022; 12(1):9311.

PMID: 35665772 PMC: 9166798. DOI: 10.1038/s41598-022-13499-1.


References
1.
Martinez P, Peters S, Stammers T, Soria J . Immunotherapy for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer. Clin Cancer Res. 2019; 25(9):2691-2698. DOI: 10.1158/1078-0432.CCR-18-3904. View

2.
Luo C, Tao Y, Zhang Y, Zhu Y, Minyao D, Haleem M . Regulatory network analysis of high expressed long non-coding RNA LINC00941 in gastric cancer. Gene. 2018; 662:103-109. DOI: 10.1016/j.gene.2018.04.023. View

3.
Wang W, Song Z, Wang Y, Zhong W, Kang P, Yang Y . Elevated long non-coding RNA LINC00958 was associated with metastasis and unfavorable prognosis in gastric cancer. Eur Rev Med Pharmacol Sci. 2019; 23(2):598-603. DOI: 10.26355/eurrev_201901_16872. View

4.
Zhao X, Sun S, Zeng X, Cui L . Expression profiles analysis identifies a novel three-mRNA signature to predict overall survival in oral squamous cell carcinoma. Am J Cancer Res. 2018; 8(3):450-461. PMC: 5883095. View

5.
Hu Q, Ye Y, Chan L, Li Y, Liang K, Lin A . Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. Nat Immunol. 2019; 20(7):835-851. PMC: 6619502. DOI: 10.1038/s41590-019-0400-7. View